Related Experiment Video
Updated: Mar 21, 2026
Use of an Influenza Antigen Microarray to Measure the Breadth of Serum Antibodies Across Virus Subtypes
Published on: July 26, 2019
Evolution of Cryptococcal Antigen Testing: What is new?
Elizabeth Nalintya1, Reuben Kiggundu1, David Meya2
1Infectious Diseases Institute, Mulago Hill Road, Makerere University, Uganda.
Abstract:
Over the last decade, an upsurge in both the frequency and severity of fungal infections due to the HIV/AIDS epidemic and the use of immunosuppressive therapy has occurred. Even diagnostic methods like culture and microscopy, which have low sensitivity and longer turn-around-times are not widely available, leading to delays in timely antifungal therapy and detrimental patient outcomes. The evolution of cryptococcal antigen (CrAg) testing to develop inexpensive and more sensitive methods to detect cryptococcal antigen is significant. These newer tests employ immunoassays as part of point-of-care platforms, which do not require complex laboratory infrastructure and they have the potential to detect early disease and reduce time to diagnosis of cryptococcal infection. Advocacy for widely available and efficacious life-saving antifungal treatment should be the only remaining challenge.
Insights
Newer cryptococcal antigen (CrAg) tests offer sensitive, point-of-care detection for fungal infections. These advancements improve early diagnosis and timely antifungal treatment, especially for HIV/AIDS patients.
Area of Science:
- Medical Mycology
- Infectious Diseases
- Diagnostic Technologies
Background:
- Increasing incidence and severity of fungal infections linked to HIV/AIDS and immunosuppressive therapies.
- Limitations of traditional diagnostic methods (culture, microscopy) including low sensitivity, long turnaround times, and limited availability.
- Significant rise in opportunistic fungal infections necessitates improved diagnostic approaches.
Purpose of the Study:
- To highlight the significance of evolving cryptococcal antigen (CrAg) testing.
- To introduce newer, sensitive, and inexpensive methods for detecting cryptococcal antigen.
- To emphasize the potential of point-of-care platforms for early cryptococcal infection diagnosis.
Main Methods:
- Development of immunoassays for cryptococcal antigen detection.
- Integration of these immunoassays into point-of-care (POC) platforms.
- Focus on technologies requiring minimal laboratory infrastructure.
Main Results:
- Newer CrAg tests demonstrate enhanced sensitivity and cost-effectiveness.
- POC platforms enable rapid detection of cryptococcal antigen.
- Potential for early disease detection and reduced diagnostic delays.
Conclusions:
- Evolving CrAg testing represents a significant advancement in diagnosing fungal infections.
- Point-of-care platforms offer a viable solution for resource-limited settings.
- Wider availability of sensitive diagnostics is crucial for timely antifungal therapy and improved patient outcomes.
